{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:03:03Z","timestamp":1773799383022,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Telitacicept is a biologic that specifically targets B-lymphocyte stimulator and a proliferation-inducing ligand, demonstrating significant potential for therapeutic applications in B-cell-mediated autoimmune diseases. Currently, telitacicept is primarily utilized in the treatment of systemic lupus erythematosus. However, its therapeutic effect on immunoglobulin A nephropathy (IgAN) after hematopoietic stem cell transplantation (HSCT) has not been reported. This case report presents the clinical outcome of telitacicept administration in the treatment of IgAN following HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>A 36-year-old Asian man developed IgAN following allogeneic HSCT for acute myeloid leukemia (AML). The patient presented with features of high-risk nephrotic syndrome, including a urinary protein quantification of 8.28\u202fg\/24\u202fh and serum albumin level of 29\u202fg\/L. The patient showed significant clinical improvement following treatment with moderate-dose glucocorticoids combined with telitacicept. After the treatment process, the urine albumin quantification decreased to 0.23\u202fg\/24\u202fh, and serum albumin increased to 45.8\u202fg\/L. During the treatment, estimated glomerular filtration rate (eGFR) increased from 67.3 to 79.83\u202fmL\/min\/1.73m<jats:sup>2<\/jats:sup>, and immune indicators immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) also demonstrated steady levels (IgA: 6.78\u201310.1\u202fg\/L, IgG: 0.5\u20131.41\u202fg\/L, IgM: 0.17\u20130.6\u202fg\/L). Notably, the patient\u2019s condition remained stable without any significant adverse effects throughout the rapid tapering of the glucocorticoid dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case suggests that telitacicept may be an effective treatment option for IgAN following HSCT, providing valuable insights into future therapeutic strategies for managing post-HSCT IgAN.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1667519","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:29:31Z","timestamp":1757914171000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Telitacicept administration improved immunoglobulin A nephropathy after hematopoietic stem cell transplantation: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Zishu","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonggao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5527\/wjn.v12.i4.82","article-title":"Immunoglobulin A vasculitis nephritis: current understanding of pathogenesis and treatment","volume":"12","author":"Amatruda","year":"2023","journal-title":"World J Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","article-title":"Contemporary review of IgA nephropathy","volume":"15","author":"Filippone","year":"2024","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4067\/s0716-97602012000300012","article-title":"Hematopoietic stem cell transplantation: clinical use and perspectives","volume":"45","author":"Barriga","year":"2012","journal-title":"Biol Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/j.ackd.2021.11.003","article-title":"Kidney disease following hematopoietic stem cell transplantation","volume":"29","author":"Abudayyeh","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1093\/ndt\/gfq645","article-title":"The role of graft-versus-host disease in haematopoietic cell transplantation-associated glomerular disease","volume":"26","author":"Hu","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/ndt\/gfp693","article-title":"Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient Iga1","volume":"25","author":"Hu","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and other HSCT-related major complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/odi.12028","article-title":"Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research","volume":"19","author":"Mays","year":"2013","journal-title":"Oral Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.bbmt.2015.12.014","article-title":"Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy","volume":"22","author":"Beyar-Katz","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2017.11.008","article-title":"Kidney pathology after hematologic cell transplantation\u2014a single-center observation study of indication biopsies and autopsies","volume":"24","author":"Girsberger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.xkme.2023.100674","article-title":"Kidney biopsy findings among allogenic hematopoietic stem cell transplant recipients with kidney injury: a case series","volume":"5","author":"Roy","year":"2023","journal-title":"Kidney Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1464616","DOI":"10.3389\/fimmu.2024.1464616","article-title":"Case report: nephrotic syndrome and portal hypertensive ascites after allogeneic hematopoietic stem cell transplantation: a rare manifestation of chronic graft-versus-host disease","volume":"15","author":"Ai","year":"2024","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/s2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2215\/cjn.00380705","article-title":"Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?","volume":"1","author":"Brukamp","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile","year":"2023","journal-title":"Clin Kidney J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00281-021-00883-8","article-title":"IgA glycosylation and immune complex formation in IgAN","volume":"43","author":"Suzuki","year":"2021","journal-title":"Semin Immunopathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1165394","DOI":"10.3389\/fimmu.2023.1165394","article-title":"Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy","volume":"14","author":"Nihei","year":"2023","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cdt3.104","article-title":"Advances in the treatment of IgA nephropathy with biological agents","volume":"10","author":"Zhuang","year":"2024","journal-title":"Chronic Dis Transl Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/ckj\/sfad023","article-title":"Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms","volume":"16","author":"Caza","year":"2023","journal-title":"Clin Kidney J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e00028","DOI":"10.1097\/imna-d-22-00028","article-title":"Diagnosis of fibrillary glomerulonephritis with positive immunoglobulin A-\u03ba deposits presenting as membranous nephropathy using immunoelectron microscopy: a case report and literature review","volume":"10","author":"Li","year":"2023","journal-title":"Integr Med Nephrol Androl"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1681\/asn.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41409-023-01951-3","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists","volume":"58","author":"Mahmoudjafari","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"995149","DOI":"10.3389\/fimmu.2022.995149","article-title":"BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis","volume":"13","author":"Jeon","year":"2022","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.3324\/haematol.2016.145409","article-title":"APRIL levels are associated with disease activity in human chronic graft-versus-host disease","volume":"101","author":"Chasset","year":"2016","journal-title":"Haematologica"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin Kidney J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fmed.2020.00092","article-title":"The role of immune modulation in pathogenesis of IgA nephropathy","volume":"7","author":"Chang","year":"2020","journal-title":"Front Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e3099","DOI":"10.1097\/md.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1667519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:29:32Z","timestamp":1757914172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1667519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":34,"alternative-id":["10.3389\/fmed.2025.1667519"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1667519","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1667519"}}